Skip to main content

Market Overview

UPDATE: Hilliard Lyons Downgrades Omega Healthcare to Long-Term Buy Following Q1 Conference Call

Share:

In a report published Thursday, Hilliard Lyons analyst John Roberts downgraded the rating on Omega Healthcare Investors (NYSE: OHI) from Buy to Long-Term Buy, but named a $43.00 price target.

In the report, Roberts noted, “Management retained its expectation of about $200 million in acquisitions and investments closing for the year, right on our expectations and in light of the low amount so far for the year. Management noted that its pipeline remains robust, and we would not be surprised to see more acquisitions made in the year than expected. We remain comfortable with our estimate, which we have bumped up to a normalized $2.56 a share, above guidance. Management gave a little color on its expectations for equity issuance for the year, noting that they would be issuing shares under OHI's equity issuance program as deal flow warrants. Management noted that they had already issued 3.8 million shares for proceeds of $107 million in Q1.”

Omega Healthcare Investors closed on Wednesday at $34.85.

Latest Ratings for OHI

DateFirmActionFromTo
Feb 2022Credit SuisseMaintainsNeutral
Feb 2022Raymond JamesMaintainsOutperform
Feb 2022Credit SuisseInitiates Coverage OnNeutral

View More Analyst Ratings for OHI

View the Latest Analyst Ratings

 

Related Articles (OHI)

View Comments and Join the Discussion!

Posted-In: Hilliard LyonsAnalyst Color Downgrades Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com